Log In
BCIQ
Print this Print this
 

PSX1002

Also known as: glycopyrronium bromide

  Manage Alerts
Collapse Summary General Information
Company Circassia Pharmaceuticals plc
DescriptionFormulation of glycopyrronium bromide, a long-acting muscarinic receptor antagonist (LAMA), delivered via pressurized metered dose inhaler (pMDI)
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat moderate to severe chronic obstructive pulmonary disease (COPD)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$152.7M

$106.9M

$45.8M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/15/2015

$152.7M

$106.9M

$45.8M

Get a free BioCentury trial today